
    
      Up to five hundred and thirty (530) subjects will be enrolled and injected with the study
      drug DWP-450 over the course of the 365 day study.

      Subjects with moderate-to-severe glabellar lines at maximum frown on the 4 point Glabellar
      Line Scale (GLS, 0=none, 1= mild, 2=moderate, 3=severe), as judged by the investigator, will
      be eligible for injection with DWP-450.

      Subjects may receive up to a maximum of 4 treatments and will be followed for 365 days from
      initial treatment.
    
  